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Adaptive immunity is initiated by T cell recognition of specific antigens presented by major histocompatibility complexes 
(MHCs). MHC multimer technology has been developed for the detection, isolation, and characterization of T cells in 
infection, autoimmunity, and cancer. Here, we present a simple, fast, flexible, and efficient method to generate many 
different MHC class I (MHC I) multimers in parallel using temperature-mediated peptide exchange. We designed conditional 
peptides for HLA-A*02:01 and H-2Kb that form stable peptide–MHC I complexes at low temperatures, but dissociate when 
exposed to a defined elevated temperature. The resulting conditional MHC I complexes, either alone or prepared as ready-
to-use multimers, can swiftly be loaded with peptides of choice without additional handling and within a short time frame. 
We demonstrate the ease and flexibility of this approach by monitoring the antiviral immune constitution in an allogeneic 
stem cell transplant recipient and by analyzing CD8+ T cell responses to viral epitopes in mice infected with lymphocytic 
choriomeningitis virus or cytomegalovirus.
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Introduction
Immune surveillance is mediated by MHC class I (MHC I) com-
plexes that bind intracellular peptides for presentation to CD8+ T 
lymphocytes. This ability to distinguish between self and foreign 
is fundamental to adaptive immunity, and failure can result in 
the development of autoimmune disease. During life, humans are 
under continuous attack by pathogens, such as viruses. Some of 
them establish lifelong infections, where the virus persists in a 
latent state without causing symptoms, but occasionally reacti-
vates. One class of such viruses causing recurring infections is 
the herpesviruses (Grinde, 2013). Normally, reactivation does 
not lead to disease, because the infection is rapidly cleared by 
T cells upon recognition of viral antigens. However, in the con-
text of transplantation, when patients are immunocompromised, 
reactivation of herpesviruses such as CMV or EBV can result in 
serious health threats (Broers et al., 2000; Green et al., 2016). It is 
therefore important to monitor virus-specific T cell numbers in 
transplant recipients to follow the fate of the recurring infections 
and to decide if intervention is needed.
Since their first use in 1996 by Altman et al., MHC multimers, 
oligomers of MHC monomers loaded with antigenic peptides and 
tagged with fluorochromes, have been the most extensively used 
reagents for the analysis and monitoring of antigen-specific T 
cells by flow cytometry (Altman et al., 1996). However, multimer 
generation involves many time-consuming steps, including 
expression of MHC I heavy chain and β2-microglubulin 
in bacteria, refolding with a desired peptide, purification, 
biotinylation, and multimerization (Altman et al., 1996). Initially, 
all these steps had to be undertaken for every individual peptide–
MHC I complex, because empty MHC I molecules are unstable 
(Ljunggren et al., 1990). This prompted the search for ways to 
generate peptide-receptive MHC I molecules at will for the 
parallel production of multiple MHC I multimers from a single 
input peptide–MHC I complex. Several techniques aimed at 
peptide exchange on MHC I have been developed by us and 
by others, including dipeptides as catalysts or periodate or 
dithionite as chemical triggers to cleave conditional ligands in 
situ, after which peptide remnants can dissociate to be replaced 
by a peptide of choice (Rodenko et al., 2009; Amore et al., 
2013; Choo et al., 2014; Saini et al., 2015). Alternatively, MHC I 
monomers are prepared with a photocleavable peptide that gets 
cleaved upon UV exposure, after which MHC I molecules can be 
loaded with peptides of choice and subsequently multimerized 
(Rodenko et al., 2006; Toebes et al., 2006; Bakker et al., 2008). 
This approach has facilitated the discovery of a myriad of 
epitopes and the monitoring of corresponding T cells (Toebes 
et al., 2006; Hadrup et al., 2009; Andersen et al., 2012; Bentzen 
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et al., 2016). However, UV exchange technology requires the use 
of a photocleavable peptide and a UV source. UV exposure and 
ligand exchange are not compatible with fluorescently labeled 
multimers, and the biotinylated peptide-loaded MHC I molecules 
need to be multimerized on streptavidin after peptide exchange. 
Other disadvantages include the generation of reactive nitroso 
species upon UV-mediated cleavage and photodamage of MHC 
I and/or exchanged peptides, while the generated heat causes 
sample evaporation (Pattison et al., 2012).
To develop a faster, more convenient technology for peptide 
exchange on multimers, we explored our original observation 
that, early in MHC I assembly, low-affinity peptides continu-
ously bind and dissociate from MHC molecules until a high-af-
finity/low–off-rate peptide is bound for presentation (Garstka et 
al., 2015). This process was strongly dependent on temperature: 
low-affinity peptides that stably associated at low temperature 
were released at slightly elevated temperatures and replaced 
with higher-affinity peptides (De Silva et al., 1999; Garstka et al., 
2015). Here, we describe a direct application of this observation: 
the design of peptides with a low off-rate at 4°C that in a tem-
perature-dependent manner can be exchanged for exogenous 
peptides of interest. We provide proof-of-concept for H-2Kb and 
HLA-A*02:01 multimers, representatives of dominant mouse 
and human MHC alleles, respectively. From a single standard 
batch of these MHC I multimers, we generated, within hours, 
multiple correctly loaded MHC I multimers, just by incubation 
with selected peptides at a defined temperature. We made many 
different MHC multimers to detect specific T cell responses in 
virus-infected mice and to measure T cell kinetics against various 
viral reactivations in a human transplant recipient. Tempera-
ture-exchangeable MHC I multimers will provide simple, fast, 
and convenient tools for epitope discovery and immune moni-
toring of large sets of potential antigenic peptides.
Results
Identification of peptide–MHC I combinations suitable for 
temperature exchange
When designing peptides suitable for MHC I temperature 
exchange, the most important criterion is that the MHC I com-
plex loaded with a conditional ligand should be stable at low tem-
peratures, but unstable at higher temperatures for replacement 
by exogenous peptides (Fig. 1 A). The main determinant for MHC 
I-peptide stability is peptide off-rate (Garstka et al., 2015). We 
have selected peptides known to bind to the respective MHC I 
molecules with low off-rates and substituted their anchor resi-
dues to increase their off-rates.
We have previously produced mouse H-2Kb complexes with 
low-affinity peptides derived from Sendai virus epitope FAP 
GNY PAL (NP324–332) and analyzed their stability and kinetics of 
peptide binding (Garstka et al., 2015). From the seven peptides 
tested, only FAP GNAPAL (boldface indicates amino acid changes 
compared to wild-type sequence) fulfilled the criteria required 
for peptide exchange. The melting temperature of the H-2Kb 
complex with FAP GNAPAL, defined as the midpoint of thermal 
denaturation, is ∼33°C (Fig. S1). In line with this, FAP GNAPAL 
swiftly dissociated from and did not rebind to H-2Kb at either of 
the two elevated temperatures tested (26°C and 32°C; Garstka et 
al., 2015). This indicates that the H-2Kb–FAP GNAPAL complex is 
sufficiently stable to refold at 4°C, but unstable at elevated tem-
peratures and could therefore be a suitable complex for tempera-
ture-induced peptide exchange.
To translate the exchange technology to human applications, 
we set out to identify a suitable peptide for HLA–A*02:01, the 
most frequently occurring human MHC I allele in the Cauca-
sian population. We designed peptides based on the HIV-1 epi-
tope ILK EPV HGV (RT476–484) with one (IAKEP VHGV or ILK EPV 
HGA) or both anchors (IAKEP VHGA) modified. HLA–A*02:01 
complexes with modified peptides were produced and thermal 
stability experiments performed, where tryptophan fluores-
cence was monitored over a wide temperature range to assess 
HLA–A*02:01–peptide complex unfolding. Out of four complexes 
tested, HLA–A*02:01–IAKEP VHGV showed the lowest melt-
ing temperature (∼38°C; Fig. S1). This melting temperature is 
lower than that of the HLA–A*02:01–antigen complexes (which 
is around 57°C, Fig. S1), providing a temperature window for 
exchange from the HLA–A*02:01–IAKEP VHGV template.
Temperature-labile peptide–MHC I monomers efficiently 
exchange for a range of peptides
We next evaluated the peptide exchange efficiency of H-2Kb in 
complex with FAP GNAPAL over a temperature range using ana-
lytical size exclusion HPLC. We found that the complex itself is 
unstable at room temperature (20°C), resulting in denaturation 
and aggregation. This is illustrated by the absence of an MHC I 
peak when analyzed by size exclusion HPLC (Fig. 1 B, in magenta). 
When incubated in the presence of a high-affinity peptide (SII 
NFE KL, OVA257–264) a clear peak was observed, demonstrating 
that H-2Kb could be “rescued’’ from unfolding (Fig. 1 B, upper 
panel; compare green to magenta). Exchange of FAP GNAPAL 
(dissociation constant [Kd] > 4 µM [Garstka et al., 2015]) for SII 
NFE KL (Kd = 1.4 nM [Vitiello et al., 1996]) was almost complete 
within 30 min. The efficiency increased only by 15% after 24 h 
(Fig. 1 B, upper panel; quantification in Fig. 1 C, gray bar).
Similarly, HLA-A*02:01 in complex with any of the four pep-
tides based on ILK EPV HGV were tested for exchange with a 
high-affinity binding peptide (vaccinia virus [VACV] B19R297–305; 
Kd = 0.06 nM [Ishizuka et al., 2009]) at different temperatures 
and time points. HLA-A*02:01 in complex with ILK EPV HGV or 
ILK EPV HGA remained stable at room temperature. Even at ele-
vated temperatures, intact HLA-A*02:01 could be detected (in 
magenta, 37 or 42°C; Fig. S2, A and B). Considering their high 
melting temperatures (∼57 and 47°C, respectively; Fig. S1) and 
dissociation constants (ILK EPV HGV − Kd = 2.5 nM [Madden et 
al., 1993]; ILK EPV HGA − Kd = 1.1 µM, predicted with NetMHC 
[Nielsen et al., 2003; Andreatta and Nielsen, 2016]), ILK EPV HGV 
and ILK EPV HGA fail as input peptides in the exchange reaction.
We continued the search for optimal peptides binding to 
HLA–A*02:01, allowing efficient temperature-induced exchange. 
Complexes of HLA–A*02:01 with IAKEP VHGV (Kd = 7.3 µM pre-
dicted with NetMHC [Nielsen et al., 2003; Andreatta and Nielsen, 
2016]) or IAKEP VHGA (Kd = 19.1  µM predicted with NetMHC 
[Nielsen et al., 2003; Andreatta and Nielsen, 2016]) were con-
siderably less stable, even at room temperature (Fig. S2, C and 
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D). As a result of higher stability, the refolding efficiency of 
HLA–A*02:01–IAKEP VHGV (at 4°C) was substantially higher 
than that of HLA–A*02:01–IAKEP VHGA (Fig. S2), as was maxi-
mum rescue with exogenous peptide WLI GFD FDV (Fig. S2, C and 
D; compare green to magenta). HLA–A*02:01–IAKEP VHGV was 
efficiently exchanged at two temperatures: at 37°C for 1 h or at 
32°C for 3 h (Fig. S2 C; compare green to magenta). We selected 
HLA–A*02:01–IAKEP VHGV as the best candidate complex for 
peptide exchange applications, despite its higher temperature 
required for optimal exchange. In conclusion, we have identi-
fied two peptide–MHC I pairs allowing efficient temperature-in-
duced exchange reactions.
When used for broad applications in immunology, MHC I mul-
timers should exchange their peptides for numerous different 
peptides, including those with a relatively low affinity, includ-
ing many tumor neoantigens (Duan et al., 2014). To test this, we 
exchanged H-2Kb–FAP GNAPAL for either FAP GNWPAL (Kd = 33 
nM at 26°C and Kd = 33 nM at 32°C [Garstka et al., 2015]) or FAP 
GNY PAA (Kd = 18 nM at 26°C and Kd = 144 nM at 32°C [Garstka et 
al., 2015]). For both suboptimal peptides, the exchange efficiency 
reached 80–90% of the level observed for SII NFE KL (Fig.  1  B; 
quantified in Fig. 1 C), as further confirmed by mass spectrome-
try (MS) analysis (Table 1). After exchange the conditional pep-
tide FAP GNAPAL could not be detected, which demonstrates that 
all peptide–MHC I complexes contained the exogenous peptide.
Detection of antigen-specific CD8+ T cells using ready-to-use 
temperature-exchanged MHC I multimers
The technology of peptide exchange would be more attractive if 
it could be applied directly on ready-made MHC I multimers, a 
severe limitation of current parallel exchange technologies. In 
current exchange technologies, monomers are first exchanged 
and then multimerized (Fig. 2 A, upper panel), but the method 
described here can be applied directly to multimers (Fig. 2 A, 
lower panel). To test this, we incubated H-2Kb-FAP GNA PAL mul-
timers, stored batch-wise at −80°C, at room temperature either 
with or without 50 µM SII NFE KL peptide. After 5 min following 
incubation, the multimers were used to stain SII NFE KL-specific 
Figure 1. Temperature-induced peptide exchange allows for the generation of MHC I complexes with high- and low-affinity peptides. (A) Schematic 
representation of temperature-induced peptide exchange on MHC I molecules. The thermolabile MHC I–peptide complex is stable at 4°C, but undergoes 
unfolding and degradation under thermal challenge (upper panel). Addition of a higher-affinity peptide stabilizes the MHC I, preventing its degradation 
(lower panel). (B) Primary data of temperature-induced peptide exchange analyzed by gel filtration chromatography at room temperature. Peptide–MHC I 
(H-2Kb–FAP GNA PAL) monomers were incubated with indicated peptides at room temperature over a range of time points. The following exchange peptides 
were used: optimal binder, SII NFE KL (ovalbumin); suboptimal binders, FAP GNW PAL or FAP GNY PAA. One of three representative experiments is shown. 
(C) The exchange efficiency was calculated from the area under the curve measured by HPLC and normalized to binding of the optimal peptide SII NFE KL 
for 1 h. Mean values ± SD from three independent experiments are shown.
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OT-I T cells. Multimers prepared by temperature exchange per-
formed indistinguishably from conventional multimers. No pos-
itive staining was observed when multimers were not exchanged 
or exchanged for an irrelevant peptide (FAP GNY PAL, Fig. 2 B). 
When assessing multimer stability upon freezing, we found that 
multimers alone suffered from freeze–thaw cycles, but addition 
of 300 mM NaCl or 10% glycerol before freezing, as published 
before (Hadrup et al., 2015), ensured stability during freeze–
thaw cycles (Fig. 2 C). We conclude that temperature-mediated 
peptide exchange can be used to produce MHC multimers with 
antigenic peptides from temperature-exchangeable multimer 
stocks within minutes. This represents a significant advantage 
by taking away any time-consuming preparation preceding mul-
timer staining experiments.
The immune responses to lymphocytic choriomeningitis 
virus (LCMV) and mouse CMV (MCMV) infections in C57BL/6 
mice have been extensively characterized, and we used these 
infections as a model to illustrate the quality of our tempera-
ture-exchanged multimers in the detection of antigen-specific 
CD8+ T cells (Matloubian et al., 1994; van der Most et al., 1998; 
Rodriguez et al., 2001; Wherry et al., 2003). We measured the 
CD8+ T cell responses to the following immunodominant epi-
topes: LCMV epitope NP238-Kb/SGY NFS LGA AV and MCMV epi-
topes M38-Kb/SSP PMF RV and IE3-Kb/RAL EYK NL (Table S1). We 
first validated exchange on H-2Kb monomers by HPLC. As for SII 
NFE KL, all three peptides could be loaded with high-efficiency 
within 5 min at room temperature and produced stable H-2Kb 
complexes, which was not observed for exchange reactions 
without peptide or with an excess of high off-rate template pep-
tide FAP GNA PAL (Fig. 3 A; quantified in Fig. 3 B). Subsequently, 
we again replaced the poorly H-2Kb–binding peptide FAP GNA 
PAL for these three viral epitopes on H-2Kb multimers and used 
these multimers, all generated from stocks stored at −80°C as 
described above, to stain blood samples from LCMV-infected 
mice or splenocytes from MCMV-infected mice. Within 5 min 
after taking the multimers with temperature-sensitive peptides 
from the freezer, the antigenic peptide-loaded multimers were 
ready and stained antigen-specific CD8+ T cells as efficiently as 
conventional multimers (Fig. 3 C), demonstrating the easy and 
broad use of temperature exchange technology.
Likewise, HLA–A*02:01–IAK EPV HGV monomers could be 
readily exchanged for selected viral epitopes (HCMV pp65-A2/
NLV PMV ATV, HCMV IE-1-A2/VLE ETS VML, EBV LMP2-A2/CLG 
GLL TMV, EBV BMLF-1-A2/GLC TLV AML, EBV BRLF1-A2/YVL DHL 
IVV, and human adenovirus [HAdV] E1A-A2/LLD QLI EEV [details 
in Table S1]), when incubated at 32°C for 3 h or 37°C for 45 min 
(Fig. 4 and Fig. S3). HPLC analysis revealed no MHC I peak after 
incubation at 32°C without peptide, indicating unfolding and 
precipitation of MHC I monomers (Fig. 4 A, magenta). However, 
incubation with peptide at 32°C for 3 h revealed a peak of MHC I 
monomers as high as the original input complexes for all peptides 
(Fig. 4 A; quantified in Fig. 4 B). Incubation at 37°C for 45 min 
likewise resulted in efficient rescue, with the exception of EBV 
BMLF-1-A2/GLC (Fig. S3). Considering the relatively low pre-
dicted affinity of this epitope (Kd = 138.63 nM predicted with Net-
MHC [Nielsen et al., 2003; Andreatta and Nielsen, 2016]), EBV 
BMLF-1-A2/GLC may not stabilize HLA-A2*02:01 sufficiently at 
elevated temperatures during a prolonged period of time. We 
selected 3-h incubation with exogenous peptides at 32°C as opti-
mal exchange condition for HLA–A*02:01. MS analysis showed 
that HLA–A*02:01–IAK EPV HGV monomers exchanged for NLV 
PMV ATV, LLD QLI EEV, GLC TLV AML, or template peptide IAK 
EPV HGV contained only the desired peptides. The rescue of the 
MHC I monomers was proportional to the predicted affinity of 
the peptides, as observed in the HPLC quantifications (Table 1 
and Fig. 4 B).
Within 3 h after addition of peptide to the preformed condi-
tional HLA–A*02:01, multimers they were ready for staining of 
CD8+ T cell clones with corresponding specificities. Detected per-
centages of multimer-positive CD8+ T cells corresponded to those 
detected using either conventional or UV-exchanged multimers, 
confirming their proper function. No staining was observed with 
multimers exchanged for irrelevant peptides (Fig. 4 C).
Exchanged MHC I-peptide multimers are effective reagents  
for immune monitoring
To demonstrate a direct application of our reagents in clinical 
practice, we compared our temperature-exchanged multimers 
with conventional multimers in an immune monitoring set-
ting. Because patients are heavily immunocompromised after 
T cell–depleted allogeneic stem cell transplantation (allo-SCT), 
T cell reconstitution is critical to prevent morbidity and mor-
tality caused by posttransplant infections with herpesviruses 
like human CMV (HCMV) and EBV (Broers et al., 2000; Green 
et al., 2016). Therefore, patients are intensively monitored until 
Table 1. Relative quantification of exchange efficiency by MS








H-2Kb FAP GNA PAL SII NFE KL 105.5 ± 4.7
FAP GNW PAL 94.2 ± 10.8
FAP GNY PAA 84.4 ± 6.2
FAP GNA PAL 4.2 ± 0.1
- 0.1 ± 0.1
SII NFE KL - 107.4 ± 12.6
HLA-A*02:01 IAK EPV HGV NLV PMV ATV 101.3 ± 13.2
LLD QLI EEV 86.0 ± 14.6
GLC TLV AML 70.7 ± 16.3
IAK EPV HGV 27.4 ± 2.7
- 7.2 ± 2.2
NLV PMV ATV - 80.5 ± 15.3
Peptide exchange on MHC I was performed with 0.5 µM monomers (H-2Kb 
or HLA-A*02:01), incubated with 50 µM peptide as described in Materials 
and methods. Monomers were also incubated in the absence of peptide 
to determine the stability of the complexes under these conditions. To 
quantify the amount of eluted peptide, standard curves were created with 
the respective synthetic peptides. H-2Kb–SII NFE KL and HLA-A*02:01– 
NLV PMV ATV were measured as positive controls.
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the donor-derived immune system has developed. Ready-to-use 
multimers are valuable immune monitoring reagents that allow 
prompt action as needed in these cases.
We exchanged PE-labeled HLA–A*02:01–IAK EPV HGV multi-
mers (stored at −80°C and exchanged following the conditions 
as described above) for a selection of HCMV- and EBV-derived 
epitopes in parallel and used these to monitor T cell frequen-
cies in peripheral blood mononuclear cells (PBMCs) obtained 
at weekly intervals after allo-SCT. The kinetics of CD8+ T cells 
specific for HCMV pp65-A2/NLV are in concordance with the 
HCMV reactivation illustrated by the expansion of HCMV viral 
DNA detected in blood (Fig. 5, upper panel). Although a positive 
EBV DNA load was measured only once, CD8+ T cells specific for 
EBV LMP2-A2/CLG, and to a lesser extent those specific for EBV 
BMLF-1-A2/GLC, expanded over time (Fig. 5, lower panel). No 
significant responses were detected against HCMV IE-1-A2/VLE 
(Fig. 5, upper panel) or EBV BRLF1-A2/YVL (Fig. 5, lower panel). 
Frequencies of specific T cells were comparable between conven-
tional and temperature-exchanged multimers. This illustrates 
the efficiency and flexibility of our technology to rapidly pro-
duce many different MHC I multimers ad hoc from a stored and 
ready-to-use stock for the detection of antigen-specific T cells, 
even at the low frequencies typically found in primary immune 
monitoring samples.
Discussion
We describe a reliable approach that allows the parallel genera-
tion of large sets of different MHC I multimers. Our approach can 
be applied in all laboratories, because it requires only a freezer 
for storage of exchangeable multimer stocks and a thermob-
lock, water bath, or PCR machine for incubation at the optimal 
Figure 2. Temperature-exchanged H-2Kb 
multimers efficiently stain antigen-specific 
CD8+ T cells. (A) Schematic representation of 
MHC I peptide exchange on monomers (exchange 
first) or on multimers (multimerization first). 
(B) Dot plots of MHC I multimer staining of spleno-
cytes from OT-I mice analyzed by flow cytometry. 
Multimers were prepared after or before exchang-
ing the template peptide for either a relevant 
peptide (SII NFE KL, OVA) or an irrelevant peptide 
(FAP GNY PAL, Sendai virus) for 30 min at room tem-
perature. Control multimers were prepared using 
conventional refolding followed by multimerization. 
One of three representative experiments is shown. 
(C) Thermolabile multimers of H-2Kb–FAP GNA PAL 
are stable over time when stored at -80°C in 
the presence of 300 mM NaCl or 10% glycerol. 
H-2Kb–FAP GNA PAL multimers were thawed and 
FAP GNA PAL was exchanged for SII NFE KL before 
staining OT-I splenocytes (performed once). Mul-
timer+ CD8+ T cells are depicted as percentage 
of total live single cells. The gating strategy is 
described in detail in Fig. S4 A.
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temperature for exchange. This system is faster and less labori-
ous than the generation of multimers from single peptide–MHC 
I combinations, either made by producing individual complexes 
by refolding and purification or by cleaving an MHC-embed-
ded peptide for chemically triggered or UV-mediated peptide 
exchange (Rodenko et al., 2006, 2009; Amore et al., 2013; Choo et 
al., 2014). Our approach allows fast and near-quantitative peptide 
exchange on multimers, whereas parallel multimer generation 
using UV-mediated exchange is variable as a result of uneven 
evaporation across and between sample plates and cannot be per-
formed on preformed MHC I multimers because of fluorophore 
bleaching. We have established a method where ready-made tem-
perature-sensitive MHC I multimers can be stored at −80°C and, 
while thawing, can be ad hoc incubated with peptides of choice 
to allow peptide exchange within 5–180 min, depending on the 
MHC I allele. This is the most robust technique for multimer pro-
duction developed to date, that will facilitate immune monitoring 
and discovery of neoantigens. We anticipate that rapid, robust, 
and inexpensive detection of MHC antigen–specific T cells will 
have a strong impact on the immune monitoring of responses 
to infection and cancer immunotherapies, as well as vaccines 
(Bentzen et al., 2016; El Bissati et al., 2016; Grassmann et al., 
2017; La Rosa et al., 2017). Immunotherapy, aimed at either sup-
pressing or enhancing cellular immune responses, has advanced 
greatly over the last decade. Several immune checkpoint inhibi-
tors, including antibodies against CTLA-4 and PD-1/PD-L1, have 
been approved for use in the clinic and have shown remarkable 
responses in the treatment of various cancers, including mel-
anoma, non–small cell lung cancer and renal cell cancer (Hodi 
et al., 2010; Page et al., 2010; Topalian et al., 2012; Robert et al., 
2014; Tumeh et al., 2014). As a consequence of checkpoint block-
ade, T cell responses elicited against neoantigens are markedly 
increased, leading to improved killing of cancer cells (Fourcade 
et al., 2009; van Rooij et al., 2013). A combination of therapies 
directed at immune checkpoints and the information in the 
cancer mutanome holds great promise in personalized cancer 
Figure 3. Temperature-exchanged H-2Kb multimers are suitable for staining antigen-specific T cells from virus-infected mice. (A–C) H-2Kb– 
FAP GNA PAL monomers (A and B) or multimers (C) were exchanged for FAP GNA PAL (Sendai virus), SII NFE KL (OVA), SGY NFS LGA AV (LCMV NP238), SSP PMF RV 
(MCMV M38), or RAL EYK NL (MCMV IE3) for 5 min at 20°C. (A) Primary data of temperature-induced peptide exchange on H-2Kb monomers analyzed by ana-
lytical gel filtration chromatography at room temperature. One of three representative experiments is shown. (B) Exchange efficiency calculated from the area 
under the curve from HPLC chromatograms normalized to the binding of optimal peptide (SII NFE KL). Mean values ± SD from three independent experiments 
(single data points depicted as gray dots) are shown. (C) H-2Kb–FAP GNA PAL multimers were exchanged for the indicated peptides and subsequently used to 
stain corresponding CD8+ T cells in PBMCs of an LCMV-infected mouse or splenocytes from an MCMV-infected mouse. Percentages of CD8+ T cells detected by 
flow cytometry were comparable between temperature-exchanged multimers and conventional multimers. Irrelevant peptide: FAP GNY PAL (Sendai virus). One 
of two representative experiments is shown. Multimer+ CD8+ T cells are indicated as percentage of total CD8+ cells. Cells were gated as described in Fig. S4 B.
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Figure 4. Temperature-exchanged HLA-A*02:01 multimers are suitable for staining virus-specific T cells. (A–C) HLA-A*02:01–IAK EPV HGV monomers 
(A and B) or multimers (C) were exchanged for HCMV pp65-A2/NLV PMV ATV, HCMV IE-1-A2/VLE ETS VML, EBV BMLF-1-A2/GLC TLV AML, EBV LMP2-A2/CLG GLL TMV, 
EBV BRLF-1-A2/YVL DHL IVV, or HAdV E1A-A2/LLD QLI EEV for 3 h at 32°C. (A) Representative chromatograms of exchange on monomers analyzed by gel 
filtration chromatography at room temperature. (B) Efficiency of exchange calculated from the area under the curve from HPLC chromatograms normalized 
to input peptide–MHC I. Mean values ± SD from five independent experiments are shown. Single data points are depicted as gray dots. (C) HLA-A*02:01– 
IAK EPV HGV multimers were exchanged for the indicated peptides and subsequently used for staining of specific CD8+ T cell clones or cell lines. Detected 
percentages of multimer-positive CD8+ T cells were comparable between temperature-exchanged multimers and conventional multimers. One of two representative 
flow cytometry experiments is shown. Multimer+ CD8+ T cells are indicated as percentage of total CD8+ cells. Cells were gated as described in Fig. S4 C.
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treatment. Identifying T cell responses against neoantigens and 
other cancer-specific epitopes will contribute to the success of 
immunotherapy, especially when combined with vaccination.
We have shown for two MHC I alleles, one mouse and one 
human, that temperature-exchanged multimers can be as effi-
cient as conventional- or UV-exchanged multimers to stain spe-
cific CD8+ T cells, including those present at low frequencies. We 
have demonstrated for both the H-2Kb–FAP GNA PAL and HLA–
A*02:01–IAK EPV HGV combinations that the temperature-labile 
input peptide may be exchanged for both high- and low-affinity 
peptides, illustrating the application for a broad array of T cell 
specificities (Fig. 1, B and C; Fig. 3; Fig. 4; and Table S1). These 
MHC I multimers loaded with desired peptides are highly spe-
cific, as no difference in background stain as compared with 
conventional or UV-exchanged multimers was observed (Fig. 2; 
Fig. 3; and Fig. 4). Their use in monitoring viral reactivation in an 
allo-SCT recipient illustrates the flexibility of temperature-ex-
changeable MHC I multimers that can be produced within hours, 
as required for clinical use (Fig. 5).
We previously showed that peptide–MHC I complexes at a 
given temperature undergo a conformational change, which 
results in full peptide dissociation (Garstka et al., 2015). Below 
this temperature, the complexes are fairly stable and, as a result 
of a high off-rate, allow exchange for a more stable low off-rate 
peptide. We designed peptides to form stable complexes with 
MHC I at low temperatures that can be released at elevated tem-
peratures. The selection of optimal peptides allowing low tem-
perature exchange and full replacement by exogenous peptides 
is not obvious. Several options include peptides with subopti-
mal length, smaller anchor residues, and altered N or C termini 
(Garstka et al., 2015). Even then, many peptide sequences have 
to be tested to identify the optimal peptide–MHC I combination, 
as we describe here for the most frequently used mouse and 
human MHC I alleles. The design of peptides suitable for tem-
perature exchange on HLA–A*02:01 proved more challenging 
than H-2Kb, possibly because of the intrinsically higher stability 
of human MHC I complexes compared with mouse MHC I. Yet, 
expanding this principle to the many other MHC I alleles could 
provide a standard procedure where viral or tumor antigens are 
sequenced, the fragments that may bind are predicted and syn-
thesized within a day, and loaded on the ready-to-use MHC I mul-
timers (as stored in the −80°C freezer). Within 2 d a patient’s T 
cell responses could then be monitored, as the production of the 
MHC I multimers loaded with the correct peptides is no longer 
the time limiting factor.
In conclusion, we present a fast, easy, and reproducible 
method for the generation of ready-to-use MHC I multimers 
loaded with epitopes at wish. This approach will render MHC 
multimer technology accessible to any research or clinical chem-
istry laboratory.
Materials and methods
Peptide synthesis and purification
Peptides were synthesized in our laboratory by standard sol-
id-phase peptide synthesis in N-methyl-2-pyrrolidone using 
Syro I and Syro II synthesizers. Amino acids and resins were 
used as purchased from Nova Biochem. Peptides were purified 
by reversed-phase HPLC using a Waters HPLC system equipped 
with a preparative Waters X-bridge C18 column. The mobile 
phase consisted of water/acetonitrile mixtures containing 0.1% 
TFA. Peptide purity and composition were confirmed by LC-MS 
using a mass spectrometer (Micromass LCT Premier; Waters) 
equipped with a 2795 separation module (Alliance HT) and pho-
todiode array detector (2996; Waters Chromatography). LC-MS 
samples were run over a Kinetex C18 column (Phenomenex) in a 
Figure 5. Temperature-exchanged HLA-A*02:01 
multimers can be used for monitoring of HCMV- 
and EBV-specific CD8+ T cells in peripheral blood 
of an allo-SCT recipient. Peripheral blood (PB) 
samples taken after allo-SCT were analyzed for 
virus-specific CD8+ T cells in relation to viral DNA 
loads (gray). The frequency of HCMV- and EBV- 
specific T cells within the CD8+ T cell populations 
was determined using temperature-exchanged 
(dark colors) and conventional (light colors) MHC I 
multimer staining analyzed by flow cytometry. 
Mean values ± SD from two experiments per-
formed on the same day are shown.
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water/acetonitrile gradient. Analysis was performed using Mass-
Lynx 4.1 software (Waters Chromatography). Peptides were puri-
fied twice if necessary.
Protein expression and purification
MHC I complexes were expressed and refolded according to 
previously published protocols (Toebes et al., 2009). Refolded 
complexes of H-2Kb were purified twice using anion exchange 
(0–1 M NaCl in 20 mM Tris-HCl, pH 8; Resource Q column) and 
size exclusion chromatography (150 mM NaCl and 20 mM Tris-
HCl, pH 8; Superdex 75 16/600 column) on an ÄKTA (GE Health-
care Life Sciences) or NGC system (Bio-Rad). We discovered that 
recovery was considerably lower when purifying using anion 
exchange and size exclusion chromatography, as compared with 
using size exclusion only, possibly caused by strong interaction 
between peptide and ion-exchange resin. Therefore, to maximize 
purification yields, refolded complexes of HLA–A*02:01 were 
purified using only size exclusion chromatography (300  mM 
NaCl and 20 mM Tris-HCl, pH 8). Purified properly folded com-
plexes were concentrated using Amicon Ultra-15 30 kD MWCO 
centrifugal filter units (Merck Millipore), directly biotinylated 
using BirA ligase where needed, purified again using size exclu-
sion chromatography and stored in 300 mM NaCl and 20 mM 
Tris-HCl, pH 8.0 with 15% glycerol at −80°C until further use.
Protein unfolding
Thermal unfolding of different H-2Kb– and HLA–A*02:01–pep-
tide complexes was determined using an Optim 1000 (Avacta 
Analytical) machine. Peptide–MHC I complexes were measured 
in 150 mM NaCl and 20 mM Tris-HCl, pH 7.5, or PBS at a pro-
tein concentration of 0.2 mg/ml. Samples were heated using a 
1°C step gradient with 30 s temperature stabilization for each 
step. Unfolding was followed by measuring tryptophan fluores-
cence emission at a range from 300 to 400 nm after excitation 
at 266 nm. Barycentric fluorescence was determined according 
to the equation
  BCMλ =  ( ∑ I [ λ ] × λ ) / ( ∑ I [ λ ] ) 
where BCMλ is the Barycentric mean fluorescence in nm, I(λ) 
is the fluorescence intensity at a given wavelength, and λ is the 
wavelength in nm.
The melting temperature (Tm) was calculated using Bary-
centric fluorescence as a function of temperature according 
to the equation
  T m = max  dBMC _____dt ( T ) 
where max is the local maximum and  dBCM _____ dt  ( T ) is the first 
derivative of Barycentric fluorescence as a function of tempera-
ture in  [ 
nm _° C ] .
Analysis was performed with Optim Analysis Software v 2.0 
(Avacta Analytical).
Multimerization of MHC I monomers
MHC I monomers were complexed with allophycocyanin (APC)- 
or PE-labeled streptavidin to form multimers for T cell analysis. 
Typically, temperature-labile peptide–MHC I complexes were 
multimerized on ice by stepwise addition of fluorochrome-la-
beled streptavidin with 1-min intervals. Full biotinylation was 
verified by HPLC. Aliquots of multimers were snap frozen in 
150 mM NaCl and 20 mM Tris-HCl, pH 7.5, containing 15% glycerol.
HPLC analysis of temperature-mediated peptide exchange
To initiate peptide exchange, 0.5 µM peptide–MHC I complex 
was incubated with 50 µM exchange peptide in 110 µl PBS under 
defined exchange conditions. After incubation exchange solu-
tions were centrifuged at 14,000 g for 1 min at room temperature, 
and subsequently, the supernatant was analyzed by gel filtration 
on a Shimadzu Prominence HPLC system equipped with a 300 × 
7.8 mm BioSep SEC–s3000 column (Phenomenex) using PBS as 
mobile phase. Data were processed and analyzed using Shimadzu 
LabSolutions software (version 5.85).
Relative exchange efficiency determined by MS
To quantify peptide exchange on H-2Kb, 0.5 µM H-2Kb mono-
mers (H-2Kb–FAP GNA PAL) were incubated with 50 µM peptide 
(SII NFE KL, FAP GNW PAL, FAP GNY PAA, or FAP GNA PAL) in PBS 
for 45 min at room temperature. For quantification of peptide 
exchange on HLA–A*02:01, 0.5 µM HLA–A*02:01 monomers were 
incubated with 50 µM peptide in PBS for 3 h at 32°C.
Before analysis, exchanged monomers were spun at 14,000 g 
for 1 min at room temperature to remove aggregates and subse-
quently purified using a Microcon 30-kD Centrifugal Filter Unit 
with Ultracel-30 membrane (Merck Millipore; preincubated 
with tryptic BSA digest to prevent stickiness of the peptides to the 
membrane) to remove unbound excess peptide. After washing 
twice with PBS and twice with ammonium bicarbonate at room 
temperature, MHC-bound peptides were eluted by the addition 
of 200 µl of 10% acetic acid followed by mixing at 600 rpm for 1 
min at room temperature. Eluted peptides were separated using 
a Microcon 30-kD Centrifugal Filter Unit with Ultracel-30 mem-
branes. Eluates were lyophilized and subjected to MS analysis.
For MS analysis, peptides were dissolved in 95/3/0.1 vol/vol/
vol water/acetonitrile/formic acid and subsequently analyzed by 
on-line nano-HPLC MS/MS using a 1100 HPLC system (Agilent 
Technologies), as described previously (Meiring et al., 2002). 
Peptides were trapped at 10 µl/min on a 15-mm column (100-
μm inner diameter [ID]; ReproSil-Pur C18-AQ, 3 µm, Dr. Maisch 
GmbH) and eluted to a 200-mm column (50-μm ID; Repro-
Sil-Pur C18-AQ, 3 µm) at 150 nl/min. All columns were packed 
in house. The column was developed with a 30-min gradient 
from 0 to 50% acetonitrile in 0.1% formic acid. The end of the 
nano-LC column was drawn to a tip (5-µm ID), from which the 
eluent was sprayed into a 7-tesla LTQ-FT Ultra mass spectrome-
ter (Thermo Electron). The mass spectrometer was operated in 
data-dependent mode, automatically switching between MS and 
MS/MS acquisition. Full scan MS spectra were acquired in the 
Fourier-transform ion cyclotron resonance (FT-ICR) with a res-
olution of 25,000 at a target value of 3,000,000. The two most 
intense ions were then isolated for accurate mass measurements 
by a selected ion-monitoring scan in FT-ICR with a resolution of 
50,000 at a target accumulation value of 50,000. Selected ions 
were fragmented in the linear ion trap using collision-induced 
dissociation at a target value of 10,000. To quantify the amount 
Luimstra et al. 
MHC class I temperature exchange
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180156
1502
of eluted peptide standard curves were created with the respec-
tive synthetic peptides.
Mice
Wild-type C57BL/6 mice (Charles River) were maintained at the 
Central Animal Facility of the Leiden University Medical Cen-
ter (LUMC) under specific pathogen-free conditions. Mice were 
infected intraperitoneally with 5 × 104 PFU MCMV-Smith (VR-
194; American Type Culture Collection), derived from salivary 
gland stocks from MCMV-infected BALB/c mice, or with 2 × 
105 PFU LCMV Armstrong propagated on baby hamster kidney 
cells. Virus titers were determined by plaque assays as published 
(Welten et al., 2015). All animal experiments were performed 
with approval of the Animal Experiments Committee of the 
LUMC and according to the Dutch Experiments on Animals Act 
that serves the implementation of Guidelines on the Protection 
of Experimental Animals by the Council of Europe and the guide 
to animal experimentation set by the LUMC.
Collection of primary human material
Peripheral blood samples were obtained from a HLA–A*02:01–
positive multiple myeloma patient after T cell–depleted allo-
SCT, after approval by the LUMC and written informed consent 
according to the Declaration of Helsinki. To monitor viral reac-
tivation EBV and HCMV DNA loads on fresh whole blood were 
assessed by quantitative PCR (qPCR). PBMCs were collected using 
Ficoll Isopaque separation (LUMC Pharmacy, Leiden, Nether-
lands) and cryopreserved in the vapor phase of liquid nitrogen. 
Virus-specific CD8+ T cell reconstitution was determined on 
thawed PBMCs by flow cytometry.
Antibodies and reagents
Ficoll Isopaque was obtained from the LUMC Pharmacy (Leiden, 
Netherlands). Fluorochrome-conjugated antibodies were pur-
chased from several suppliers. V500 anti-mouse CD3, FITC anti–
mouse CD8, FITC anti–human CD4, Pacific Blue anti–human CD8, 
and APC anti–human CD14 were purchased from BD Biosciences. 
BV605 anti–mouse CD8 was purchased from BioLegend. Fluo-
rochrome-conjugated streptavidin and 7-AAD were purchased 
from Invitrogen. DAPI was purchased from Sigma. Conventional 
HLA–A*02:01 PE-labeled tetramers were produced by K.L.M.C. 
Franken, M.G.D. Kester, and L. Hageman (LUMC, Leiden, Nether-
lands) as described previously (Altman et al., 1996). Human IL-2 
was purchased from Chiron. Human serum albumin was pur-
chased from Sanquin Reagents.
Flow cytometry analysis of mouse CD8+ T cells
H-2Kb–FAP GNA PAL multimers were exchanged for selected pep-
tides for 5 min at room temperature and subsequently used for 
staining of the H-2Kb–restricted OVA257–264–specific TCR trans-
genic line (OT-I), described previously (Hogquist et al., 1994). Gen-
erally, 200,000 cells were stained first with APC- or PE-labeled 
temperature-exchanged or conventional multimers for 10 min at 
room temperature and then with surface marker antibodies (anti–
CD8-FITC) at 4°C for 20 min. Cells were washed twice with and 
then resuspended in FACS buffer (0.5% BSA and 0.02% sodium 
azide in PBS). DAPI was added at a final concentration of 0.1 µg/ml. 
Samples were measured using a flow cytometer (FAC SAria Fusion; 
BD Biosciences) and data were analyzed with FAC SDiva software 
(version 8.0.2; BD Biosciences; gating strategy in Fig. S4).
Virus-specific T cells were analyzed in blood samples of LCMV-
infected mice after erythrocyte lysis or splenocytes obtained 
from MCMV-infected, 8–10-wk-old mice (infected at 6–8 wk). 
Erythrocytes were lysed using a hypotonic ammonium chloride 
buffer (150 mM NH4Cl and 10 mM KHCO3, pH 7.2 ± 0.2). Cells were 
simultaneously stained with appropriate temperature-exchanged 
multimers and surface markers (7-AAD, anti–CD3-V500, and 
anti–CD8-BV605) for 30 min at 4°C. Multimers were titrated to 
establish optimal T cell staining. Generally, a dilution of 1:20–1:40 
was sufficient to stain 10,000–100,000 T cells in 50 µl FACS buffer. 
Cells were washed twice with and resuspended in FACS buffer. 
Sample data were acquired using a flow cytometer (Fortessa; BD 
Biosciences) and analyzed using FAC SDiva software (version 8.0.2; 
BD Biosciences; gating strategy in Fig. S4).
Flow cytometry analysis of human CD8+ T cells
Multimers of HLA–A*02:01–IAK EPV HGV were exchanged for 
selected peptides at 32°C for 3 h and used to stain correspond-
ing CD8+ T cells. UV-exchanged multimers were produced and 
exchanged following published protocols (Rodenko et al., 2006; 
Toebes et al., 2006). Clones or cell lines of the indicated viral 
T cell specificities (cultured in IMDM supplemented with 10% 
human serum and 100 IU/ml IL-2) were mixed with PBMCs of 
a HLA–A*02:01–negative donor to be able to discriminate mul-
timer-positive from multimer-negative cells. After incuba-
tion with PE-labeled temperature-exchanged, conventional or 
UV-exchanged multimers for 10 min at 4°C, cells were stained 
with surface marker antibodies (anti–CD8-Pacific Blue and anti–
CD14-APC) for 20 min at 4°C. Multimers were titrated to establish 
optimal T cell staining without background. Cells were washed 
twice with and resuspended in FACS buffer (0.5% human serum 
albumin in PBS). Samples were acquired using a flow cytometer 
(FAC SCanto II; BD) and analysis was performed with FAC SDiva 
software (version 8.0.2; BD Biosciences; gating strategy in Fig. 
S4). Absolute numbers of multimer positive CD8+ T cells were 
calculated based on the percentage of multimer positive cells 
within the CD8+ T cell population and the concentration of CD8+ 
T cells in whole blood.
Online supplemental material
Fig. S1 shows the thermal denaturation of selected peptide–MHC 
I complexes analyzed to determine melting temperatures. Fig. S2 
demonstrates the temperature stability of HLA–A*02:01 in complex 
with peptides of the ILK EKV HGV series, investigated using ana-
lytical gel filtration chromatography. Fig. S3 shows that exchange 
of HLA–A*02:01–IAK EPV HGV at 37°C for 45 min is efficient for 
high-affinity peptides, but not for low-affinity peptides. Fig. S4 
illustrates the gating strategies used in flow cytometry experiments. 
Table S1 lists all peptides and Kds mentioned in this article.
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